Marine Bioactive Products as Potential Antileishmanial Therapeutics

Marine Bioactive Products as Potential Antileishmanial Therapeutics

Muhammad Adil, Pragya Tiwari, Mavara Iqbal, Shamsa Kanwal, Aisha Umar
Copyright: © 2023 |Pages: 25
DOI: 10.4018/978-1-6684-6737-4.ch013
OnDemand:
(Individual Chapters)
Available
$37.50
No Current Special Offers
TOTAL SAVINGS: $37.50

Abstract

Leishmaniasis is a vector-borne, protozoal disease affecting a huge number of humans and animals across the world, particularly in developing countries. Recently, chemotherapeutic agents constitute the mainstay of treatment strategies against leishmaniasis. Nevertheless, the clinical effectiveness is compromised by their toxic effects and growing protozoal resistance. Consequently, the exploration and development of relatively safer and more effective, alternative therapeutics are critically required to combat this major health hazard of global significance. Marine habitats are rich in a wide range of chemical substances, with unique structural patterns and diverse pharmacological actions. This chapter describes the pharmacological basis, therapeutic implications, and safety profile of marine bioactive products as potential antileishmanial drugs.
Chapter Preview
Top

2. Contemporary Antileishmanial Drugs And Their Limitations

Due to a lack of specific and effective vaccines, chemotherapeutic agents (including pentavalent antimonials, paromomycin, amphotericin B, pentamidine, and miltefosine), constitute the basis of curative modalities for leishmaniasis. Among the described chemotherapeutic agents, only pentavalent antimonials are regarded as true antileishmanial drugs.

Complete Chapter List

Search this Book:
Reset